The new patent is valid until May 2035.
The biotechnology firm also said it filed a continuation patent application to expand the patent coverage to other aspects of the drug.
Meanwhile, AIkido said it entered into another deal with its contract manufacturer, Parimer Scientific, to use a newly developed manufacturing process for DHA-dFdC.
The new manufacturing process will enable the production of "several thousand milligrams" of the drug for use in formulation development and stability studies, the company said.
AIkido shares were 1.4% higher in morning trading.
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|